growing awareness and diagnosis of rare diseases are expected to boost the growth of the global plasma fractionation market at a CAGR of 6.74% during the forecast period 2023 to 2032

Market Research Future (MRFR) has published on the “Global Plasma Fractionation Market”.

The plasma fractionation market is estimated to register a CAGR of 6.74% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the Global Plasma Fractionation Market— CSL (Australia), Grifols S.A. (Spain), Takeda Pharmaceutical Company Limited (Japan), Octapharma AG (Switzerland), Pfizer, Inc (US), Bio Products Laboratory Ltd (UK), Kedrion S.p.A (Italy), ADMA Biologics, Inc (US), Japan Blood Products Organization (Japan), and KM Biologics (Japan).

Market Highlights

The global plasma fractionation market is expected to register a CAGR of 6.74% during the forecast period and is estimated to reach USD 53.01 billion by 2032.

The global plasma fractionation market is emerging due to the increasing demand for Plasma-Derived Medicinal Products (PDMPs), growing awareness and diagnosis of rare diseases, and the rising geriatric population across the globe. Additionally, the growing technological advancements and innovation will provide growth opportunities for the market in the future. However, the emergence of recombinant therapies as an alternative to plasma-derived medicines might hamper the market's growth in the forecast period.

Access full report @ https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397

Segment Analysis

The global plasma fractionation market has been segmented based on Product, Method, Application, and End User.

On the basis of the product, the market is segmented into immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others. The immunoglobulin segment held the majority share in the market in 2022. The immunoglobulin segment is further segmented into intravenous immunoglobulins, subcutaneous immunoglobulins, and others. Intravenous immunoglobulins (IVIg) offer several advantages, such as rapid delivery, high efficacy, versatility, and relatively low safety. This is being utilized in conditions such as immune thrombocytopenia (ITP), Kawasaki disease, and Guillain-Barre syndrome, among others. Moreover, subcutaneous immunoglobulins (SCIg) are commonly given in Variant Creutzfeldt-Jakob disease, Hepatitis B, Hepatitis C, human immunodeficiency virus (HIV), and among others.

On the basis of the method, the market is segmented into cryoprecipitation, chromatography, ethanol precipitation, ultrafiltration, and others. The cryoprecipitation segment held the largest market share in 2022 and is the fastest-growing segment during the forecast period. Cryoprecipitate is the precipitated fraction formed after thawing FFP (fresh frozen plasma) at 4°C. This method of isolation involves pooling cryoprecipitate from FFP collected from numerous donors. Cryoprecipitate contains high levels of factor VIII, von Willebrand factor, factor XIII, and fibronectin. Limited availability of human plasma and therapeutic advantages of cryoprecipitation are the drivers responsible for the growth of the segment.

On the basis of application, the market is segmented into immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others. The neurology segment held the largest market share in 2022, and hemato-oncology segment is the fastest-growing segment during the forecast period i.e., 2022-2032. Increasing incidences of diseases such as immune disorders, respiratory diseases, infectious diseases, cancer, and among others, rising awareness of the plasma fractionation products to treat above mentioned diseases, growing expansion of the plasma fractionated products in developing regions to fulfill the demand of patients and physicians are burgeoning the growth of the application segment.

On the basis of end user, the market is segmented into hospitals & clinics, clinical research laboratories, academic institutes, and others. The hospitals & clinics segment held the largest market share in 2022, and academic institutes segment is the fastest-growing segment during the forecast period i.e., 2022-2032. Increasing number of surgical procedures and growing number of surgical procedures are the factors driving the end user segment.

Regional Analysis

The global plasma fractionation market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe plasma fractionation market comprises of Germany, France, the UK, Italy, Spain, Belgium, and the Rest of Europe. The plasma fractionation market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World plasma fractionation market comprises of Middle East, Africa, and Latin America.

North America plasma fractionation market is experiencing significant growth, driven by factors such as increasing demand for plasma-derived therapies, advancements in biopharmaceutical research, and the rising prevalence of chronic diseases. Plasma fractionation, a crucial process in the production of various therapeutic products, involves separating plasma into its component parts, such as proteins and antibodies, for the treatment of conditions like immunodeficiency disorders and hemophilia. The region's well-established healthcare infrastructure, technological innovations, and favorable regulatory environment contribute to the market's expansion.

Europe plasma fractionation market is witnessing notable growth, fueled by various factors contributing to the demand for plasma-derived therapies. The region's sophisticated healthcare infrastructure, coupled with a rising incidence of chronic diseases, drives the need for innovative treatment options. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the number of adults diagnosed with diabetes in the EU has nearly doubled over the last two decades, from around 17 million in 2000 to 33 million in 2019, with a projected increase to 38 million by 2030.

The Asia Pacific plasma fractionation market is experiencing substantial growth, propelled by a confluence of factors that underscore the increasing demand for plasma-derived therapies in the region. The robust economic development, expanding healthcare infrastructure, and a growing awareness of advanced medical treatments contribute to the market's expansion. According to HT Digital Streams Ltd (India), the central and state governments' budgeted healthcare expenditures reached 2.1% of GDP in FY23 and 2.2% in FY22, up from 1.6% in FY21.  

Moreover, the Rest of the World is segmented into the Middle East, Africa, and Latin America. The plasma fractionation market in the above-mentioned regions is witnessing noteworthy growth, driven by a convergence of factors highlighting the escalating demand for plasma-derived therapies in these regions. With evolving healthcare infrastructures and increasing awareness of advanced medical treatments, the market is experiencing a surge in demand.

Key Findings of the Study

• The global plasma fractionation market is expected to reach USD 53.01 billion by 2032, at a CAGR of 6.74% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market.


• Based on product, the Immunoglobulin segment was attributed to holding the largest market in 2022.


• CSL (Australia), Grifols S.A. (Spain), Takeda Pharmaceutical Company Limited (Japan), Octapharma AG (Switzerland), and Pfizer, Inc (US) are the key market players.